美国食品和药物管理局批准优先审查AstraZeneca的Calquence在未经治疗的地幔细胞淋巴瘤中. FDA grants Priority Review for AstraZeneca's Calquence in untreated mantle cell lymphoma.

亚盛的血液癌症药物Calquence (acalabrutinib) 已获得FDA的优先审查,用于治疗未经治疗的上衣细胞淋巴瘤 (MCL) 的成年人. AstraZeneca's blood cancer drug, Calquence (acalabrutinib), has received Priority Review from the FDA for treating adults with untreated mantle cell lymphoma (MCL). 预计FDA的决定将在2025年初发布. The FDA's decision is expected by early 2025. 临床试验显示，与标准化疗相比，Calquence 联合苯达莫司汀和利妥昔单抗可将疾病进展或死亡减少 27%。 Clinical trials showed Calquence, combined with bendamustine and rituximab, reduced disease progression or death by 27% compared to standard chemotherapy. 卡尔昆斯已经在之前治疗后被批准用于MCL患者. Calquence is already approved for MCL patients after prior therapy.

October 03, 2024

9 文章